While nausea, vomiting, and diarrhea are the most commonly reported gastrointestinal adverse effects with GLP-1-based therapies (occurring in 15-40% of patients depending on the agent and dose), FDA prescribing information for several of these medications does list dyspepsia (indigestion) and, in some cases, gastroesophageal reflux disease (GERD) as reported adverse reactions
Unlimited Provider Visits Nutrition & Mental Health Coaching 1-on-1 Dietitian Support Unlimited Provider Visits Nutrition & Mental Health Coaching 1-on-1 Dietitian Support 100% Needle-Free Unlimited Provider Visits Nutrition & Mental Health Coaching 1-on-1 Dietitian Support Unlimited Provider Visits Nutrition & Mental Health Coaching 1-on-1 Dietitian Support *Compounded medications have not been evaluated or approved by the FDA for safety, efficacy, or quality
Improved pharmacovigilance and standardized adverse event reporting would enhance understanding of risk-benefit profiles for individual GLP-1RAs and indications
So, more for my own resource, Im dropping Gabor in here, at least until I find the Peak Human podcast episode where he describes the anatomy of the gut and the biochemistry of gut hormones effects even more clearly: Released from cells in the proximal intestine (closer to stomach) 26252069 585 KB Released from cells in the distal intestine (further from the stomach, closer to the large bowel) 16671618 367 KB This was the podcast where I first listened about Semaglutide/ GLP-1 agonist micro-dosing